Skip directly to content

Vizimpro® ▼ (dacomitinib monohydrate)

For more information on this product please visit the electronic Medicines Compendium (eMC)

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-DAC-GBR-0035 / June 2019